Renheng Pharm Ltd.

Primary Objective: To evaluate the pharmacokinetic characteristics and bioequivalence of a single oral dose of cefoperazone hydrochloride granules (test formulation: 50 mg (C17H19N5O6S2), Sponsor: Guangzhou Renheng Pharmaceutical Technology Co., Ltd.) and reference formulation (C17H19N5O6S2, Licensee: SHIONOGI & Co., LTD.) in healthy adult Chinese participants under fasting and postprandial conditions. Secondary Objective: To investigate the safety and palatability of cefoperazone hydrochloride granules (test formulation: 50 mg (C17H19N5O6S2)) and reference formulation (C17H19N5O6S2) in healthy adult Chinese participants.

To investigate the pharmacokinetic characteristics of a single subcutaneous administration of salmon calcitonin injection (test preparation T, strength: 1mL:50IU) provided by Guangzhou Yanlord Pharmaceuticals Co., Ltd. or salmon calcitonin injection (reference preparation R, trade name: Miacalcin®, strength: 1mL:50IU) certified by Future Health Pharma GmbH to healthy subjects, evaluate the bioequivalence and safety of the two preparations, and provide a basis for the registration application of the test preparation.

Primary objective: To study the pharmacokinetic characteristics of salmon calcitonin injection (test preparation T, specification: 1mL: 50IU) provided by Guangzhou Yanheng Pharmaceutical Technology Co., Ltd. or salmon calcitonin injection (reference preparation R, trade name: Miacalcin®, specification: 1mL: 50IU) certified by Future Health Pharma GmbH when administered to healthy subjects by subcutaneous injection, to evaluate the bioequivalence and safety between the two preparations, and to provide a basis for the registration application of the test preparation. Secondary objective: To explore the changes in type I collagen cross-linked C-terminal peptide (β-CTx) when the same dose of salmon calcitonin injection (specification: 1mL: 50IU) test preparation or reference preparation is administered.